Morepen Laboratories (Small Cap - Potential Multibagger) Share Target 2025, 2026 To 2035
|
Morepen Laboratories Limited |
|||
|
Price: ₹66.19 (-1.75%) | ||
| 52 Week Low: ₹38.55 52 Week High: ₹100.90 |
|||
| Market Capital: 4,057.59 Crore (Smallcap) | |||
| Healthcare -> Drug Manufacturers - Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Morepen Laboratories Share Price Target For 2025
- 1.1.1: Morepen Laboratories Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Morepen Laboratories Share Price Target For 2026
- 1.2.1: Morepen Laboratories Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Morepen Laboratories Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Morepen Laboratories Brief Company Overview
- 4: Morepen Laboratories Financial Performance
- 4.0.1: Is Morepen Laboratories A Good Buy For Long Term?
Morepen Laboratories, a Small Cap company in the Drug Manufacturers - Specialty & Generic Industry has delivered 356.8% returns in 5-year showing 4.2% quarterly revenue growth with 7.4% profit margin, making it a potential Multibagger.
To predict the Morepen Laboratories's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Morepen Laboratories Share Price Target For 2025
The line chart displays the monthly closing prices of Morepen Laboratories with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Morepen Laboratories shares in 2025, see the table below.
Morepen Laboratories Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 77.48 (+17.05%) | Price Action: 11 Nov 2024 Low |
| 2025 Target 2 | 76.7 (+15.87%) | Price Action: 27 Dec 2024 Low |
| 2025 Target 1 | 75.56 (+14.15%) | Price Action: 29 Oct 2024 Low |
| Current Price | 66.19 | Morepen Laboratories's share price as of 22 Jan 2025 |
| Stop Loss 1 | 61.89 (-6.5%) | Price Action: 12 Aug 2024 High |
| Stop Loss 2 | 61.26 (-7.45%) | Price Action: 19 Aug 2024 Low |
| Stop Loss 3 | 60.5 (-8.6%) | Price Action: Jan 2022 High |
Short-Term Technical Outlook
Current Technical Position: Morepen Laboratories is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹74.07 serves as the nearest technical reference point.
Historical Returns: 3-month: -15.66% | 6-month: +12.85% | 1-year: +27.59%
Morepen Laboratories Share Price Target For 2026
The line chart displays the monthly closing prices of Morepen Laboratories with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Morepen Laboratories shares in 2026, see the table below.
Morepen Laboratories Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 119.05 (+79.86%) | Fibonacci Extension Level 123.60% |
| 2026 Target 2 | 117.26 (+77.15%) | Price Action: Chart |
| 2026 Target 1 | 116.1 (+75.4%) | Fibonacci Extension Level 64.90% |
| Current Price | 66.19 | Morepen Laboratories's share price as of 22 Jan 2025 |
| Stop Loss 1 | 54.67 (-17.41%) | Price Action: 15 Jul 2024 Low |
| Stop Loss 2 | 54.05 (-18.35%) | Price Action: 20 Jun 2024 Low |
| Stop Loss 3 | 53.5 (-19.18%) | Price Action: 22 Feb 2024 High |
Long-Term Technical Outlook
52-Week Range Analysis: Morepen Laboratories is currently trading at 44.3% of its 52-week range (₹38.55 - ₹100.9).
Long-Term Trend Analysis: The stock shows mixed long-term signals, trading near key moving averages.
Long-Term Performance: 1-year: +27.59% | 3-year: +31.71% | 5-year: +356.75%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Morepen Laboratories Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹66.19 | ||
| 2025 | ₹140.69 | +112.55% | ₹142.80 |
| 2026 | ₹231.60 | +64.61% | ₹235.07 |
| 2027 | ₹332.41 | +43.52% | ₹337.40 |
| 2028 | ₹457.36 | +37.58% | ₹464.22 |
| 2029 | ₹570.24 | +24.68% | ₹578.79 |
| 2030 | ₹800.31 | +40.34% | ₹812.31 |
| 2031 | ₹1,104.42 | +37.99% | ₹1,120.99 |
| 2032 | ₹1,405.93 | +27.3% | ₹1,427.02 |
| 2033 | ₹1,814.36 | +29.05% | ₹1,841.58 |
| 2034 | ₹2,306.58 | +27.12% | ₹2,341.18 |
| 2035 | ₹2,936.05 | +27.29% | ₹2,980.09 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Morepen Laboratories Brief Company Overview
Morepen Laboratories Limited: A Leading Pharmaceutical and Healthcare Provider Established in 1984, Morepen Laboratories Limited is a renowned pharmaceutical and healthcare company headquartered in Gurugram, India. With a global presence, Morepen develops, manufactures, and...
markets a wide range of products, including: APIs: Anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-gout, anti-depressant, and anti-malarial drugs. Formulations: Nutrition, probiotics, gastroenterology, antibiotics, gynecology, anti-allergic, central nervous system, cardiology, diabetology, and nutraceuticals. Home Health Products: Air purifiers, sphygmomanometer, blood glucose test strips, blood pressure monitors, breathe free vaporizers, stethoscopes, digital thermometers, blood glucose monitors, nebulizers, heat belts, and pulse oximeters. OTC Products: Dr. Morepen brand fever, pain, fiber, acidity, burn, and probiotic supplements. Morepen Laboratories Limited is committed to providing high-quality healthcare solutions to its customers. The company's focus on innovation and customer satisfaction has earned it a strong reputation in the industry.Morepen Laboratories Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 4,057.59 Crore | Market valuation of Morepen Laboratories's shares. |
| Revenue (TTM) | 1,774.79 Crore | Total revenue generated by Morepen Laboratories over the past twelve months. |
| Net Income (TTM) | +131.28 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +10.66% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +7.39% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+4.2% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+63.9% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
3.01 | Company's total debt divided by total shareholder equity. |
| Total Debt | 33.49 Crore | Sum of Morepen Laboratories's current & long-term financial obligations. |
| Total Cash | 186.42 Crore | Total amount of liquid funds available to Morepen Laboratories. |
| Beta | 1.48 | Beta is greater than 1 indicating that the Morepen Laboratories's price is more volatile than the market. |
Is Morepen Laboratories A Good Buy For Long Term?
No valid response content found
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
